Startup profile · funding coverage
Braveheart
Late-clinical biotech developing HCM therapy BHB-1893 (Hengrui-partnered).
Stage
series a
Status
private
Coverage
full
Why Braveheart is interesting
Large crossover launch for hypertrophic cardiomyopathy asset competing in a crowded cardio metabolic market — a16z holds ~14% per IPO filings.
Key facts
- Series A (Nov 2025): $185M launch round with a16z Bio + Health participation (Braveheart Bio)
- Co-investors not in VCT directory: Forbion, OrbiMed, Frazier Life Sciences, Enavate Sciences
- Source: https://www.braveheart.bio/news/braveheart-bio-launches
- VCT directory co-investors: none mapped (non-directory syndicates noted above); reviewed 2026-07-24
Investors in our directory
Funds linked from Braveheart's profile — open a fund page for stage focus and related deal articles.
Industries
Generalist Technology
Industry hub pages are rolling out from our fund-derived baseline taxonomy.
Related funding articles
Venture Capital Tracker pieces that cover Braveheart's financing or category context.
Last updated: 2026-07-24